The Latest Cardiac and Vascular News
– Collaboration with Xontogeny provides funding and key advisory support for early development – MALVERN, Pa.–(BUSINESS WIRE)–Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today announced their launch with a seed investment from Xontogeny, LLC […]
AI-powered algorithms provide physicians the tools to further elevate the standard of care for structural heart patients ALISO VIEJO, Calif.–(BUSINESS WIRE)–Building on its foundational strength in partnering with health systems to close gaps in care for structural heart patients, today egnite, Inc. launched a new suite of predictive algorithms for […]
RED DESERT data of all patients confirm: alfapump DSR is highly effective at managing fluid and sodium balance in diuretic-resistant heart failure patients without need for loop diuretics restoration of diuretic response and improvement in cardio-renal function improvement in diuretic response maintained in long-term follow-up SAHARA DESERT study in heart failure […]
Final Analysis From Open-Label Extension Study in Patients with Human Immunodeficiency Virus and Dyslipidemia THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) open label extension trial of patients living with HIV who have high cholesterol, […]
CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company’s lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic […]
2,100 patients enrolled in randomized controlled trial to evaluate a precision-testing pathway for suspected coronary artery disease REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced the completion of patient enrollment in the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) randomized controlled trial. Physicians from more […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the presentation of additional preclinical data from the company’s gene editing programs for the treatment of atherosclerotic cardiovascular disease (ASCVD), the most common form of cardiovascular […]
− Initiates Clinical Study of Biannual Dosing Regimen of Investigational Vutrisiran in hATTR Patients with Polyneuropathy, with Data Expected in 2022 Potentially Supporting sNDA Submission – − Introduces New ATTR Program Aimed at Achieving Annual Dosing Regimen with Highly Potent and Reversible Effects; Expected IND Filing at or Around Year-end 2022 – […]
BE’ER SHEVA, Israel, and SHENZHEN, China , May 10, 2021 /PRNewswire/ — DiA Imaging Analysis Ltd. (DiA), a leading provider of AI-powered ultrasound analysis solutions today announced that it has partnered with SonoScape Medical Corporation (300633.SZ), a leading developer and manufacturer of ultrasound systems. As part of the partnership, SonoScape’s ultrasound devices will provide DiA’s ultrasound artificial intelligence analysis solutions […]
VANCOUVER and MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (“COSIMA”) trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who […]
